Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by InnoCare Pharma
< Previous
1
2
3
Next >
InnoCare Announces Approval of a Phase II Clinical Trial of TYK2 Inhibitor ICP-488 for Sjögren's Syndrome in China
May 07, 2026
From
InnoCare Pharma
Via
GlobeNewswire
InnoCare Announces Approval of Clinical Trial of Novel CDH7 targeted ADC ICP-B208 in China
May 06, 2026
From
InnoCare Pharma
Via
GlobeNewswire
InnoCare Announces First Patient Dosed in Phase III Trial of Orelabrutinib for SLE
April 28, 2026
From
InnoCare Pharma
Via
GlobeNewswire
InnoCare Releases 2026 Q1 Results: Strong Revenue Growth and Sustained Profitability
April 23, 2026
From
InnoCare Pharma
Via
GlobeNewswire
Preclinical Data of Novel B7-H3 ADC ICP-B794 Unveiled at 2026 AACR, Demonstrating Superior Anti-Tumor Activity and Safety
April 21, 2026
From
InnoCare Pharma
Via
GlobeNewswire
InnoCare Releases 2025 Results and Business Highlights, Achieving First Annual Profit
March 25, 2026
From
InnoCare Pharma
Via
GlobeNewswire
InnoCare Announces First Healthy Volunteer Dosed in Clinical Trial of Novel VAV1 Degrader ICP-538 in China
March 15, 2026
From
InnoCare Pharma
Via
GlobeNewswire
InnoCare’s next-generation TRKi Zurletrectinib Receives Priority Review for the Treatment of Pediatric Patients with Solid Tumors in China
March 01, 2026
From
InnoCare Pharma
Via
GlobeNewswire
InnoCare Announces Key Developments of Critical Clinical Studies
February 25, 2026
From
InnoCare Pharma
Via
GlobeNewswire
InnoCare Announces First Patient Dosed in the Phase II/III Clinical Trial of Novel TYK2 Inhibitor Soficitinib for Chronic Spontaneous Urticaria in China
February 12, 2026
From
InnoCare Pharma
Via
GlobeNewswire
InnoCare Announces IND Approval to Initiate Clinical Trial of VAV1 Degrader ICP-538 in China
February 08, 2026
From
InnoCare Pharma
Via
GlobeNewswire
Study Results of Novel TYK2 Inhibitor Soficitinib in Patients with AD Published by JAMA Dermatology
January 29, 2026
From
InnoCare Pharma
Via
GlobeNewswire
InnoCare Announces NMPA Approval of a Phase II Clinical Trial of TYK2 Inhibitor ICP-488 for Cutaneous Lupus Erythematosus
December 23, 2025
From
InnoCare Pharma
Via
GlobeNewswire
InnoCare Announces Approval of Phase II/III Clinical Trial of Novel TYK2 Inhibitor Soficitinib for Chronic Spontaneous Urticaria in China
December 17, 2025
From
InnoCare Pharma
Via
GlobeNewswire
InnoCare Announces Achievement of Primary Endpoint in Phase IIb Study of Orelabrutinib for SLE and Approval of Phase III Clinical Trial
December 14, 2025
From
InnoCare Pharma
Via
GlobeNewswire
InnoCare Announces Approval of the Next-Generation TRK Inhibitor Zurletrectinib in China
December 11, 2025
From
InnoCare Pharma
Via
GlobeNewswire
Over 20 Studies of InnoCare’s Orelabrutinib Presented at the 67th Annual Meeting of the American Society of Hematology (ASH)
December 09, 2025
From
InnoCare Pharma
Via
GlobeNewswire
Latest Data of InnoCare’s Novel BCL2 Inhibitor Presented at the 67th Annual Meeting of the American Society of Hematology (ASH)
December 08, 2025
From
InnoCare Pharma
Via
GlobeNewswire
InnoCare Announces First Patient Dosed in the Global Phase II Clinical Trial of TYK2 Inhibitor Soficitinib for Treatment of Prurigo Nodularis
November 27, 2025
From
InnoCare Pharma
Via
GlobeNewswire
InnoCare Announces First Patient Dosed in Clinical Trial of Novel ADC ICP-B794 in China
October 30, 2025
From
InnoCare Pharma
Via
GlobeNewswire
Latest Data of InnoCare's Zurletrectinib Orally Presented at SIOP 2025
October 29, 2025
From
InnoCare Pharma
Via
GlobeNewswire
InnoCare Announces Approval of HIBRUKA (Orelabrutinib) for the Treatment of Marginal Zone Lymphoma in Singapore
September 07, 2025
From
InnoCare Pharma
Via
GlobeNewswire
InnoCare Announces First Patient Dosed in the Registrational Trial of BCL2 Inhibitor Mesutoclax for Treatment of BTKi-treated MCL Patients in China
August 21, 2025
From
InnoCare Pharma
Via
GlobeNewswire
InnoCare Releases 2025 Interim Results and Business Highlights
August 19, 2025
From
InnoCare Pharma
Via
Business Wire
InnoCare Announces Approval of Clinical Trial of a Novel ADC ICP-B794 in China
July 03, 2025
From
InnoCare Pharma
Via
Business Wire
Data of InnoCare’s Robust Hemato-Oncology Pipelines Presented at the European Hematology Association (EHA) 2025 Congress
June 12, 2025
From
InnoCare Pharma
Via
Business Wire
Latest Data of InnoCare’s Robust Oncology Pipelines Presented at the 2025 ASCO Annual Meeting
June 01, 2025
From
InnoCare Pharma
Via
Business Wire
InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor Mesutoclax for Myelodysplastic Syndromes in China
May 28, 2025
From
InnoCare Pharma
Via
Business Wire
InnoCare Announces the Approval of Minjuvi® (Tafasitamab) in Combination with Lenalidomide for the treatment of Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma in China
May 21, 2025
From
InnoCare Pharma
Via
Business Wire
InnoCare Announces First Patient Dosed in the Phase II/IIII Clinical Trial of TYK2 Inhibitor Soficitinib for Treatment of Vitiligo in China
May 16, 2025
From
InnoCare Pharma
Via
Business Wire
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
